Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Debord

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Annals of the New York Academy of Sciences|December 14, 2002
Paraoxonase 1 activity: a new vascular marker of dementia?Thierry F Dantoine, Jean Debord, Louis Merle, et al.
Therapeutic Drug Monitoring|February 24, 2023
Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant RecipientsMarc Labriffe, Ludovic Micallef, Jean-Baptiste Woillard, et al.
Clinical Pharmacokinetics|February 5, 2002
Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplantsFrédéric Leger, Jean Debord, Yann Le Meur, et al.
Therapeutic Drug Monitoring|March 9, 2011
Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimusFranck Saint-Marcoux, Jean Debord, François Parant, et al.
British Journal of Clinical Pharmacology|February 20, 2020
Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patientsMarc Labriffe, Julien Vaidie, Caroline Monchaud, et al.
Therapeutic Drug Monitoring|May 21, 2005
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periodsAurélie Prémaud, Yannick Le Meur, Jean Debord, et al.
Clinical Pharmacokinetics|September 12, 2009
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantationFranck Saint-Marcoux, Bernard Royer, Jean Debord, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patientsJean-Baptiste Woillard, Vincent Lebreton, Michael Neely, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|August 11, 2016
Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration DataNadia Ben Fredj, Jean Baptiste Woillard, Jean Debord, et al.
Therapeutic Drug Monitoring|November 5, 2020
Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant RecipientsPierre Marquet, Florine Cros, Ludovic Micallef, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Annals of the New York Academy of Sciences|December 14, 2002
Paraoxonase 1 activity: a new vascular marker of dementia?Thierry F Dantoine, Jean Debord, Louis Merle, et al.
Therapeutic Drug Monitoring|February 24, 2023
Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant RecipientsMarc Labriffe, Ludovic Micallef, Jean-Baptiste Woillard, et al.
Clinical Pharmacokinetics|February 5, 2002
Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplantsFrédéric Leger, Jean Debord, Yann Le Meur, et al.
Therapeutic Drug Monitoring|March 9, 2011
Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimusFranck Saint-Marcoux, Jean Debord, François Parant, et al.
British Journal of Clinical Pharmacology|February 20, 2020
Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patientsMarc Labriffe, Julien Vaidie, Caroline Monchaud, et al.
Therapeutic Drug Monitoring|May 21, 2005
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periodsAurélie Prémaud, Yannick Le Meur, Jean Debord, et al.
Clinical Pharmacokinetics|September 12, 2009
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantationFranck Saint-Marcoux, Bernard Royer, Jean Debord, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patientsJean-Baptiste Woillard, Vincent Lebreton, Michael Neely, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|August 11, 2016
Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration DataNadia Ben Fredj, Jean Baptiste Woillard, Jean Debord, et al.
Therapeutic Drug Monitoring|November 5, 2020
Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant RecipientsPierre Marquet, Florine Cros, Ludovic Micallef, et al.
Pageof 4